Zenocutuzumab (MCLA-128) 是一种双特异性人源化 IgG1 抗体,包含两个不同的 Fab 臂,靶向HER2和HER3的细胞外结构域。
生物活性 | Zenocutuzumab (MCLA-128) is a bispecific humanizedIgG1antibody containing two different Fab arms, targeting extracellular domains ofHER2andHER3[1]. |
体外研究 (In Vitro) | Zenocutuzumab(0.001-1000 nM;96 小时)抑制肺癌和乳腺癌细胞系的细胞生长[1]。 Zenocutuzumab(0.1-1000 nM;24 小时)抑制 HER3 和 AKT 磷酸化,在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物[1]。
Cell Viability Assay[1] Cell Line: | Human bronchiolar epithelial cell lines (HBEC) | Concentration: | 0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM | Incubation Time: | 96 h | Result: | Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions. |
Western Blot Analysis[1] Cell Line: | HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells | Concentration: | 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM | Incubation Time: | 24 hours | Result: | Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation. |
|
体内研究 (In Vivo) | Zenocutuzumab(2.5-25 mg/kg;腹腔注射;每周一次;持续 28 天)导致生长显着减少,包括肿瘤消退[1]。
Animal Model: | 6 to 12-week-old female NSG(TM) (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1]. | Dosage: | 2.5 mg/kg, 8 mg/kg, or 25 mg/kg | Administration: | i.p.; once weekly; for 28 days | Result: | Blocked growth of lung and ovarian cancer PDX models. |
|
CAS 号 | |
中文名称 | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |